

CLINICAL ADVISORY

November | 2023

PharMerica

Novavax COVID-19 Vaccine (Adjuvanted) Authorized and Available for Use

BACKGROUND

On 10/3/2023, the FDA amended the emergency use authorization (EUA) of **Novavax COVID-19 Vaccine, Adjuvanted** (hereafter referred to as Novavax COVID-19 Vaccine) to the 2023-2024 formula, revised to include spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5. The original Novavax COVID-19 Vaccine is no longer authorized for use.

The authorization and availability of this updated **protein subunit vaccine** brings the total array of currently licensed or authorized adult COVID-19 vaccines to three (3): Spikevax®, Comirnaty®, and Novavax COVID-19 Vaccine.

PharMerica previously shared a [Clinical Advisory](#) and [Did You Know](#) on the two former 2023-24 COVID-19 vaccines: **Spikevax** (Moderna) and **Comirnaty** (Pfizer), which are similarly **monovalent** and **updated to the 2023-24 formula**, but which in contrast are **fully licensed** and **mRNA-based**.

Novavax COVID-19 Vaccine is emergency use authorized in individuals ≥12 years of age as follows:

- **Individuals previously vaccinated with any COVID-19 vaccine:** 1 dose of Novavax COVID-19 Vaccine is administered ≥2 months after receipt of the last previous dose of an original monovalent or bivalent COVID-19 vaccine.
- **Individuals not previously vaccinated with any COVID-19 vaccine:** 2 doses of Novavax COVID-19 Vaccine are administered 3 weeks apart.
- **Immunocompromised individuals:** an additional dose of Novavax COVID-19 Vaccine may be administered ≥2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula). Additional doses of Novavax COVID-19 Vaccine may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances. The timing of the additional doses may be based on the individual's clinical circumstances.

ORDERING INFORMATION

- Place resident orders as you would for other Part B vaccines (e.g., influenza or pneumococcal vaccines).

Skilled Nursing Facility 2023-2024 COVID-19 Vaccine Pricing		
Product	PharMerica Per Dose Cost	CMS National Payment Allowance
MODERNA - SPIKEVAX 2023-24(12Y+) SYRINGE	\$ 125.00	\$ 145.92
MODERNA - SPIKEVAX 2023-24(12Y+) SDV	\$ 125.00	\$ 145.92
NOVAVAX - COVID-19 VACCINE(12Y+) MDV (5 doses)	\$ 125.00	\$ 148.20
PFIZER - COMIRNATY 2023-24(12Y+) SDV	\$ 125.00	\$ 131.10

DOCUMENTATION/BILLING INFORMATION

- For adults with Medicare, COVID-19 Vaccines are reimbursed under Medicare Part B, even if in Part A stay.

CPT/HCPCS Code	Labeler Name	Vaccine Name	National Payment Allowance	Effective Dates
90480	-	COVID-19 Vaccine Administration	\$40.00	9/11/23 – TBD
91320	Pfizer-BioNTech	COMIRNATY (2023-24 Formula)	\$131.10	9/11/23 – TBD
91322	Moderna	SPIKEVAX (2023-24 Formula)	\$145.92	9/11/23 – TBD
91304	Novavax	Novavax COVID-19 Vaccine	\$148.20	07/13/22 – TBD


CLINICAL **ADVISORY**

November | 2023

PharMerica

Novavax COVID-19 Vaccine (Adjuvanted) Authorized and Available for Use

Recommended updated (2023–2024 Formula) COVID-19 vaccines for people who are **NOT** moderately or severely immunocompromised*†



ADDITIONAL RESOURCES
[CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States](#)

[CDC’s Recommended updated \(2023–2024 Formula\) COVID-19 vaccines for people who are NOT moderately or severely immunocompromised](#)

[CDC’s Recommended updated \(2023–2024 Formula\) COVID-19 vaccines for people who ARE moderately or severely immunocompromised](#)

[FDA Fact Sheets for Health Care Providers and Patients](#)

*For information about administration intervals and children who transition from age 4 years to age 5 years, see [Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines](#).
 †COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.